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We present a strategy to identify developmental/diﬀerentiation and plasma membrane marker genes of the most primitive human
Mesenchymal Stem Cells (hMSCs). Using sensitive and quantitative TaqMan Low Density Arrays (TLDA) methodology, we
compared the expression of 381 genes in human Embryonic Stem Cells (hESCs), hESC-derived MSCs (hES-MSCs), and hMSCs.
Analysis of diﬀerentiation genes indicated that hES-MSCs express the sarcomeric muscle lineage in addition to the classical
mesenchymal lineages, suggesting they are more primitive than hMSCs. Transcript analysis of membrane antigens suggests that
IL1R1
low,BMPR1B
low,FL T4
low,LRR C32
low,andCD34maybegoodcandidatesforthedetectionandisolationofthemostprimitive
hMSCs.TheexpressioninhMSCsofcytokinegenes,suchasIL6,IL8,orFLT3LG,withoutexpressionofthecorrespondingreceptor,
suggests a role for these cytokines in the paracrine control of stem cell niches. Our database may be shared with other laboratories
in order to explore the considerable clinical potential of hES-MSCs, which appear to represent an intermediate developmental
stage between hESCs and hMSCs.
1.Introduction
A major challenge in developmental biology is to decipher
geneexpressioncontrollingstemnessanddiﬀerentiationnet-
works. A more practical goal is to identify among these genes
those encoding membrane antigens such as receptors, which
couldbeusedasmarkerstotrackorselectstemcellsfromthe
earliestpluripotentcellstothelatestadultprogenitorcells.In
thisstudy,weanalyzedgeneexpressioninpluripotenthuman
Embryonic Stem Cell lines (hESCs), in human multipotent
bone marrow Mesenchymal Stem Cells (hMSCs), and in
hESC-derived MSCs (hES-MSCs). It is well known that
hMSCs constitute a heterogeneous population that may
include a subset of more primitive cells [1–3]. Although
many antibodies directed at cell membrane antigens have
been used to select speciﬁc hMSC populations [4–6], there is
no cogent evidence that some of these antibodies may select
foramoreprimitivepopulationwithenlargeddiﬀerentiation
potential and robust self-renewal capacity. Even in the
mouse, where such a primitive population has been recently
characterized by the expression of the cytoskeletal protein
nestin [7], separation according to membrane phenotype is
not yet feasible.
In a previous study [8], we observed that a 24h pretreat-
mentofStro1+/GlycoA−orCD45−/GlycoA−hMSCswitha
monoclonal antibody blocking the human type I interferon-
alpha (IFNα) receptor, or with a polyclonal anti-IFNα
antibody,resultedinamarkedincreaseinthenumberofvery
large colonies (Colony-forming Units-ﬁbroblasts containing
more than 3000 cells). Interestingly, these activated High2 Stem Cells International
Proliferative Potential-Quiescent hMSCs (HPP-Q hMSCs)
expressed SSEA-3 and -4 at a higher level than non-pretrea-
ted cells, suggesting that HPP-Q hMSCs constituted a more
primitive cell population than nontreated cells.
A more direct way to characterize the most primitive
hMSCs would be to select them from hESCs induced to
diﬀerentiate into hMSCs, using various procedures that
we and others have implemented [9–13]. In the present
work, we have studied hESC-derived MSCs (hES-MSCs)
assuming that these cells might represent a more primitive
hMSC population. We compared the expression proﬁles
of diﬀerentiation genes and genes encoding cytokine and
adhesion molecules and their receptors in the three pop-
ulations hESCs, hES-MSCs and hMSCs, focusing on the
genes that are diﬀerentially detected in hES-MSCs, and
hMSCs. Our data conﬁrmed previous results on hMSC gene
expression [14–20]. Moreover, the comparison of hES-MSCs
with hMSCs has revealed subtle and signiﬁcant variations in
the expression of genes that may help characterize the more
primitive hMSCs.
Our team and other investigators have shown that
primitive hematopoietic stem cells or early keratinocytes
which self-renew without diﬀerentiation, express low levels
of receptors and respond to low concentrations of cytokines
[21–29]. In contrast, the same cytokines at high concen-
trations frequently induce diﬀerentiation. We address in
this study the question of whether some Receptorlow cells
might represent within hES-MSCs the most primitive hMSC
population with a greater mesodermal potential.
hMSCsarenotonlythestemcellsforskeletalconnective-
tissue (osteoblasts, chondrocytes, and adipocytes), but are
also important components of stem cell niches [1, 7, 30–32].
Here we have studied the expression by hMSCs of transcripts
for cytokines and extracellular matrix (ECM) components in
the absence of their receptors, in keeping with the paracrine
regulation of hematopoietic stem cells. We have also studied
the possibility that hMSCs themselves express receptors to
respond to cytokines produced by other cells of the stem cell
niche.
The identiﬁcation of marker genes expressed at low
levels in primitive stem cells requires the application of
highly sensitive and reliable molecular techniques. We chose
a TaqMan Low Density Array (TLDA) to identify the
diﬀerentially expressed genes. TaqMan assays are based
on PCR, resulting in an increase of detectable reporter
ﬂuorescence in each cycle. This reliable technique, associated
withstatisticalanalyses,allowstheidentiﬁcationofbiological
markers, which could have been overlooked by less sensitive
t e c h n i q u e ss u c ha sm i c r o a r r a y s .
Finally, we propose to share with other laboratories our
database to promote better understanding of the consider-
able clinical potential of hESCs, hES-MSCs, and hMSCs (see
list of genes available in supplementary material available on
line at doi:10.4061/2011/368192).
2.MaterialsandMethods
2.1. Cell Lines and Culture Conditions. This research adheres
to the guidelines established by the National Academy of
Sciences, USA, the French Bioethics Laws, and the Agence
Franc ¸aisedeS´ ecurit´ eS a n i t a i r ed e sP r o d u i t sd eS a n t´ e (AFSS-
APS).
2.1.1. Human Embryonic Stem Cell Lines (hESCs). Pluripo-
tent Human Embryonic Stem cell lines (hESCs), hES2 and
hES3,wereprovidedbyESCellInternational(ESI,Singapore
and Australia). hESCs were cultured according to the sup-
plier’s instructions. Brieﬂy, hES2, and hES3 were ampliﬁed
in an undiﬀerentiated state on Murine Embryonic Fibroblast
(MEF) feeders on tissue culture plates precoated with 0.1%
gelatin (Sigma). Culture medium (KO-SR) consisted of
80% knockout Dulbecco’s Modiﬁed Eagle’s Medium (KO-
DMEM) (Invitrogen), 20% KO Serum Replacement (KO-
SR, Invitrogen), 1mM L-glutamine (Invitrogen), 0.1mM β-
mercaptoethanol (Sigma), 1% (v/v) Non-Essential Amino
Acids (NEAA), and 4ng/mL human basic Fibroblast Growth
Factor(bFGF)(Preprotech).Themediumwasrenewedevery
day.
hESC colonies were replated every 6 to 7 days by mass
culture passaging (Geron protocol) summarized as follows:
hESC cultures were washed once with PBS and treated with
1mg/mL collagenase IV. Colonies were scraped into clumps
and replated with a 1 to 6–8 ampliﬁcation rate.
MEF were prepared as described elsewhere [33]a n du s e d
at the cell density of 6.3 × 104cells/cm2.B r i e ﬂ y ,M E Fw e r e
treated by Mitomycin C and maintained in high glucose
DMEM supplemented with 10% (v/v) selected fetal calf
serum.
2.1.2. Human Mesenchymal Stem Cells Derived from Human
Embryonic Stem Cells (hES-MSCs). Two diﬀerent cell lines
were used. The ﬁrst one, MSC-P51R (hES-MSC1), gener-
o u s l yp r o v i d e db yO l i v i e re ta l .[ 10] was obtained from
hESC H1 [34] spontaneously diﬀerentiated in D10 medium
and 7.5% of CO2. After 1 to 3 passages, the cultures
became morphologically homogeneous. The second line,
hES-MSC2, derived from hES2 in our laboratory, was
obtainedfromEmbryoidBodies (EBs)obtained after36days
of culture in EB medium [33]. EBs were cut, plated in 6-
well plates (Falcon) previously coated with puriﬁed human
ﬁbrinogen (2mg/mL, 1mL/well) for 30min at 37◦Ca n d
further maintained in culture on ﬁbrinogen in EB medium
during 4 weeks. After dissociation by trypsin, cells were
centrifuged, counted, and plated at 1.104cells/cm2 in six-well
tissue culture plates previously coated with gelatin 0.1% in
hMSC medium (see bone marrow cell isolation section).
2.1.3. Human Bone Marrow Mesenchymal Stem Cells
(hMSCs). Human Mesenchymal Stem Cells (hMSC1 and
hMSC2) were obtained during orthopedic surgery after
informed consent of the donors. Brieﬂy, mononuclear cells,
recovered after Ficoll density gradient centrifugation were
plated at 6.103 cells/cm2 in six-well tissue culture plates
(Falcon, Becton Dickinson) or in 75cm2 tissue culture ﬂasks
(Falcon). The volume of culture medium was modiﬁed
according to cell density. hMSC medium consisted in
αMEM without nucleotides (Invitrogen) and without antibi-
otics, but supplemented with 10% selected Hyclone serumStem Cells International 3
(Perbio Science) and 2mM glutamine (Invitrogen). Cells
were allowed to adhere for 48h at 37◦C and 5% CO2.
Wells were then washed twice and the remaining adherent
cells were further cultured in the same medium. Cells were
cultured with medium renewal twice a week for 14 days
and every 6 to 7 days after the ﬁrst passage, reaching
no more than 70–80% conﬂuency. hMSCs were replated
as follows: hMSCs were washed twice in PBS, treated
for 5 to 10min by trypsin/EDTA (Boehringer, Ingelheim,
Germany), centrifuged, counted and replated. All cultures
were incubated in a HeraCell (Heraeus) incubator at 37◦C
in an atmosphere containing 5% CO2 and 95% humidity.
2.2. Diﬀerentiation Potentials and Immunophenotypic Studies
Are Described in Supplementary Material Data and in Previ-
o u sW o r k[ 8, 10, 14, 17]. See Supplementary Material and
Methods, table, and ﬁgure.
2.3. RNA Isolation and Gene Expression Analysis by
Quantitative Real-Time PCR (qRT-PCR)
2.3.1. cDNA Preparation. hESCs, hES-MSCs, and hMSCs
were harvested using buﬀer RLT lysis buﬀer (Qiagen) fol-
lowing the manufacturer’s protocol. Total RNA was prepared
according to standard protocols and RNA samples were then
stored at −80◦C. Five micrograms of RNA were treated by
DNase RNase-free (Ambion) to avoid genomic DNA con-
tamination in subsequent RT-PCR. One microgram of total
RNAwasreverse-transcribedina20μLﬁnalreactionvolume
using the High Capacity cDNA Reverse Transcription Kit
with RNase inhibitor (Applied Biosystems) following the
manufacturer’s instructions.
2.3.2. Quantitative PCR Reaction. Quantitative PCR reac-
tions were performed using ABI Prism 7900 HT sequence
detectionsystem(AppliedBiosystems).MicroﬂuidicTaqman
arrays were designed to measure the expression of 381 genes.
Brieﬂy, 300ng of cDNA were used per sample-loading port,
each allowing 48 q-PCR reactions following the manufac-
turer’s instructions (10min 94.5◦C followed by 40 cycles of
30sec at 97◦C and 1min at 59.7◦C). GAPDH was used to
normalize gene expression levels for further analysis of q-
PCR experiments with the relative quantiﬁcation method
[35].
2.3.3. Quantitative PCR Experiment Analysis. Analysis was
performed with biological duplicates. Relative Quantiﬁca-
tion (RQ) values were calculated for each gene according to
the publication of Vandesompele’s group [36] with the con-
trol group (hESCs) as reference and an arbitrary threshold at
35 cycles. In order to minimize variations between cell lines,
we analyzed data in biological groups as follows: hES2 and
hES3 for the hESC group; hES-MSC1 and hES-MSC2 for
the hES-MSC group; two samples of human bone marrow
MSCs derived from diﬀerent patients for the hMSC group.
Results shown are the average in each biological group and
are expressed as means ± SD. Data were also analyzed with
StatMiner 4.1 software (Integromix, Madrid, Spain) and a P
value was computed using a moderated t-test to measure the
signiﬁcance associated with each RQ value. Variations were
considered statistically signiﬁcant when the P value was <
0.05. Hierarchical clustering was obtained using StatMiner
software and Pearson’s test on the 381 genes tested.
Q-PCR data are usually represented as relative quantiﬁ-
cations (RQ = 2−ΔΔCt ). The ΔCt values depend on the
expression level of the chosen reference genes. In this study
we used a modiﬁed ΔCt calculation according to Weksberg
et al. [37], which takes into account the variations of the
ΔCt from one tissue sample to the other. Brieﬂy, for a given
sample A, the ΔCt is calculated by subtracting the reference
gene value (Ct (REF)) from the Ct value of the gene of
Interest X (Ct (X) A): ΔCt(X)A = Ct(X)A − Ct(REF)A. The
Normalized Ct (NCt) is calculated in 2 steps as follows: we
ﬁrst calculate the variation of the reference gene in sample
A (VCt (REF) A) as: VCt (REF) A = Ct (REF) A − Mean Ct
(REF) all samples. Then we calculate the Normalized Ct for
the gene of interest X in sample A (NCt (X) A): NCt (X) A =
Ct (X) A – VCt (REF) A. Neuroectodermic, endodermic,
mesodermic, chondrocytic, and osteoblastic diﬀerentiation
genes are represented in Figure 1 with the 2−NCt method.
Chosen cutoﬀ value for 2−NCt was 3.10−11, that is, above
threshold value for any transcript included in this study.
3. Results and Discussion
We studied the transcription level of genes representative
of extracellular matrix components, cytokine families and
their receptors, and other diﬀerentiation genes in three cell
populations: hESCs, hES-MSCs, and hMSCs. The Ct values
are normalized Ct (NCt) (see Materials and Methods). All
N C tv a l u e sa r eg i v e ni nT a b l e s1 .
3.1. Transcriptomic Hierarchical Clustering. We investigated
the expression of transcripts characterizing diﬀerentiation
pathways. As shown in Figure 1 for all 381 transcripts
studied, hES-MSCs and hMSCs clustered in one main
group while hESCs clustered into another. This hierarchical
clustering analysis indicated that hES-MSCs were more
closely related to hMSCs than to hESCs.
3.2. Diﬀerentiation Markers. We compared the expression
level of speciﬁc embryonal lineage transcripts in the 3 popu-
lations of hESCs, hES-MSCs, and hMSCs. Results are shown
on Figures 2(a) and 2(b). We found that hES-MSCs and
hMSCs, as compared to hESCs, expressed signiﬁcantly (P<
0.05) less neuroectodermic (NRCAM, NEUROD1, ASCL1,
PAX6, GFAP, and NEFH) (Figure 1(a)) and endodermic
(CDH1, ONECUT1, HNFA4, AFP, TTR, FOXA1, FOXA2,
ALB, and TCF1) (Figure 1(b)) markers.
We also observed progressive and signiﬁcant decrease
from hESCs to hES-MSCs and an absence of detection in
hMSCs of the mesodermal sarcomeric (skeletal and car-
diac) muscle genes MYH2, SOX2, TNNI1, ACTA1, GATA4,
HAND2 and NKX2.5. SOX2 was the only gene which
was not signiﬁcantly expressed in hES-MSCs. In contrast
HAND2, and NKX2.5 had a maximal expression in hES-
MSCs. (Figure 1(c)). These results conﬁrm the mesodermal
commitment and the more primitive state of hES-MSCs4 Stem Cells International
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Figure 1: Hierarchical clustering of normalized Ct of 380 genes on
hESCs, hES-MSCs, or hMSCs using individual samples and genes.
Genes are classiﬁed using StatMiner Software and the Pearson test.
compared to hMSCs [9, 10, 38–40]. Our data validate
previous works reporting that rare hMSC subpopulations
cangenerateskeletalmusclecellsinadditiontomesenchymal
and vascular smooth muscle cells [1]. This is also the case for
the embryonic C3H10T1/2 line, taken as surrogate for MSCs
in many studies [41–43].
Finally, from hESCs to hMSCs, we found a progressive
increase in the expression level of mesenchymal genes impli-
cated in chondrogenesis and/or osteogenesis (the transcrip-
tion factors SOX9 and RUNX2, the cell adhesion molecules
BST1 and ITGB2, the protease MMP13, and the extra-
cellular matrix components AGC1, COL1A2, COL10A1,
COMP, DCN, BGN, NID2, SPARC, and POSTN) (Figures
1(d) and 1(e)). For most of these transcripts the progressive
increase was signiﬁcant indicating again that hES-MSCs
are more primitive than hMSCs as they are less expressing
mesenchymal diﬀerentiation markers.
These results conﬁrm that hES-MSCs represent a more
primitive mesenchymal population than hMSCs [9, 10, 38–
40], indicating that the lineage priming [17] of hES-MSCs
includes the sarcomeric muscle lineage in addition to the
classical mesenchymal lineages.
Flow cytometry and diﬀerentiation studies on the 3
populations are provided in supplementaary material to
conﬁrmotherpublishedresultsonhES-MSCsandtovalidate
our transcriptomic studies.
3.3. Cytokines and Receptors
3.3.1. TGF-β Superfamily. Many genes related to the TGF-β
superfamily (15 genes evaluated) were detected at relatively
high levels in all three cell populations.
TGF-β1 was the cytokine with the highest level of expre-
ssion in the TGF-β superfamily, with NCt of 27.6 (hESCs),
22.8 (hES-MSCs), and 21.0 (hMSCs). TGF-β2 and INHBA
encoding the Activin monomer, were also highly expressed
(Tables 1). We have previously demonstrated that TGF-β1a t
physiologicalconcentrations,below1ng/mL,preventsdiﬀer-
entiation during self-renewal of both adult and embryonic
stem cells [21, 23, 28, 44].
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Figure 2: Diﬀerentiation gene expression levels in hESC (blue),
hES-MSC (Red), or hMSC (green) populations. The diﬀerentiation
genes are classiﬁed as follow: (a) neuroectodermic genes; (b)
endodermic genes; (c) mesodermic genes; (d) and (e) mesenchymal
genes including transcription factors, cell adhesion molecules, and
protease genes (d) and Extra-cellular matrix genes (e). y-axis values
correspond to 2−NCt as described in Material and Methods. The
blacklinerepresentsthelimitofdetection (LOD: >35Ct).Asterisks
(∗) indicate signiﬁcant expression variation with P<0.05.Stem Cells International 5
As expected, TGFBR1 and TGFBR2 were both well and
stably expressed in the three populations (Tables 1).
BMP7 was not detected in hES-MSCs and hMSCs, but
was highly expressed in hESCs (NCt = 26.2) (Tables 1).
BMPR1B, a BMP receptor Type I, was well expressed
in hESCs (NCt = 29.4), 3-fold less in hES-MSCs (NCt =
31.2) and not detected in hMSCs (Figure 3(a)). Comparison
of our data on hES-MSCs versus hMSCs suggests that
BMPR1Blow cells should be further investigated to select the
more primitive hMSC subpopulation. BMPR1B has indeed
been used to characterize MIAMI cells (Marrow Isolated
Adult Multilineage Inducible cells) that present a larger
proliferation and diﬀerentiation potential than that of the
hMSCs used in the present study [45].
Latent TGF-beta plays an important role in stem cell
regulation.Itisamajorcomponentofthestemcellnicheand
is present throughout the ECM. Latent TGF-beta represents
as o u r c eo fa c t i v eT G F - β, which can be released via various
proteolytic activities when required by neighboring stem
cells [23]. LRRC32 (also known as GARP for Glycoprotein
A Repetitions Predominant) is a latent TGF-beta receptor
located at the cell membrane [46]. This molecule was
detected in hESCs and hES-MSCs and was upregulated
in hMSCs (Tables 1 and Figure 3(b)), which raises the
possibility that an hMSC subpopulation similar to hES-
MSCs, might be selected according to its low expression of
LRRC32.
3.3.2. Interleukin Family. IL6 was expressed in hESCs (NCt =
32.8) and hES-MSCs (NCt = 31.3). This expression was
upregulated 76 times in hMSCs (NCt = 26.6) (Figure 3(c)).
This IL6 upregulation was associated with the mentioned
above upregulation of TGF-β1, a cytokine reported as
inducing IL6 [47]. Interestingly, the IL6R gene was slightly
but stably expressed in all samples tested (NCt = 30) (Table,
1). The IL6 transducer signal gene, IL6ST, encoding for a
gp130 protein, was also upregulated with an NCt = 25.6 for
hESCs, 23.4 for hES-MSCs and 22.5 for hMSCs.
IL1R1 (Figure 3(d)) was up-regulated in hES-MSCs and
hMSCs (12 and 50 fold up-regulation, resp.) as compared
to hESCs (NCt = 30.8), which raises the possibility that an
hMSC subpopulation might be selected according to its low
expression of IL1R1.
IL8wasexpressedinthethreepopulations,butIL8recep-
tors were detected in none. This suggests that IL8 expression
could control a paracrine mechanism in stem cell niches.
Finally,anIL1pathwayinhibitor,IL1R2,wasexpressedat
low level (NCt = 33) only in hMSCs, suggesting the presence
of a negative feedback loop to control IL1 expression level in
these cells. IL1R2 is a molecular decoy that traps interleukin
1 but does not initiate subsequent signaling, suppressing
therefore the inﬂammatory response in some autoimmune
diseases [48].
3.3.3. Tumor Necrosis Factor (TNF) Family. TNF-alpha was
expressed at low levels in hESCs and hES-MSCs (NCt = 33.7
and 32.7 resp.; Tables 1), but not in hMSCs.
The ﬁve TNF family receptors studied were expressed in
all three cell populations. TNFRSF1A (unlike TNFRSF1B)
was detected at relatively high levels in hESCs and hES-
MSCs, and both TNF receptors were up-regulated, about 5-
fold, in hMSCs. TNFRSF5 encoding the CD40 antigen was
detectedatarelativelyhighlevelinthethreecellpopulations.
TNFRSF11A was downregulated and TNFRSF11B was up-
regulated in both hES-MSCs and hMSCs as compared to
hESCs. The upregulation of TNFRSF11B/OPG in hMSCs
may be related to the osteogenic lineage priming of the cells,
since this gene is a reliable osteoblastic marker.
These results suggest that hMSCs are responsive to TNF
produced by nearby cells as they express TNF receptors
but not the TNF ligand itself. The TNF promoter has been
recently described to be silenced by methylation in hMSCs,
an observation which partially conﬁrms our results [20].
3.3.4. Pituitary Hormone Family. PTHR1 was down-regu-
lated 20 times in hES-MSCs (NCt = 31.5) and not detected
in hMSCs as compared to hESCs (NCt = 27.2) (Figure 3(e)).
This gene codes for the pituitary hormone receptor able
t oi n t e r a c tw i t hm a n yo t h e rp a t h w a y ss u c ha sT G F - β [49]
and Wnt [50]. PTHR1 expression is consistently increased
in hMSCs diﬀerentiating into osteoblasts and chondrocytes
[17, 51]. As already suggested above for other receptors,
an hMSC subpopulation, similar to hES-MSCs, might be
selected according to its low expression of PTHR1.
3.3.5. VEGF Receptor—FLT Receptors. FLT1/VEGFR1 was
well expressed by hESCs but signiﬁcantly down-regulated
in both hES-MSCs and hMSCs. FLT3/CD135 was detected
at a low level in hESCs, but not in hES-MSCs and hMSCs.
However,wedetectedtheFLT3ligand,FLT3LG,atarelatively
highlevelinallthreecellpopulations.SincehMSCsrepresent
a major component of the hematopoietic stem cell niche,
they could provide FLT3 ligand for early hematopoietic stem
cells which are strongly activated by this cytokine.
FLT4/VEGFR3 is the only gene of this family that
we found to be signiﬁcantly down-regulated in hMSCs
compared to hES-MSCs (Figure 3(f)). Indeed, this gene was
well expressed in hESCs (NCt = 28.9), but down-regulated
about 26 times in hES-MSCs and undetectable in hMSCs.
As already suggested above for other receptors, this receptor
might be a potential candidate to select a more primitive
hMSC subpopulation.
3.3.6. PDGF. PDGFA was expressed at high levels in all
three cell populations (Tables 1). PDGFB was highly down-
regulated, about 400-fold (Figure 3(g)) in hES-MSCs as
compared to hESCs (NCt = 25.3) and was undetectable in
hMSCs. PDGF-B promotes diﬀerentiation of hMSCs [52].
This diﬀerentiation could be induced by PDGF-B produced
by neighboring cells of the niche.
3.3.7. Wnt Pathway. We tested 23 genes from the Wnt
family: 8 Wnt cytokines, 3 Frizzled (FZD) receptors, and 12
coregulators. The products of these genes form an important
signaling pathway involved in many cellular processes such
as diﬀerentiation control. All these 23 genes were expressed
in one or more of the three populations.6 Stem Cells International
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Figure 3: Transcriptomic expression analyses of potential markers for primitive hMSC selection. Relative gene expression of hESC-derived
hMSC (hES-MSC) or hMSC populations compared to hESC calibrator group. Messenger RNA levels were determined using QRT-PCR, and
relative quantiﬁcation (RQ) values were calculated by the 2−ΔΔCt method with GAPDH as internal control and an arbitrary threshold at 35
cycles. Asterisks (∗) indicate signiﬁcant expression variation with P value < 0.05. As compared to hESC calibrator group, arrows pointing
downwards (↓) indicate gene extinction (>35Ct) and arrows pointing upwards (↑) indicate gene appearance (<35Ct).Stem Cells International 7
Most WNT genes were expressed at a low level in hESCs
and down-regulated (WNT1, WNT10B, WNT16) or not
detected (WNT3A and WNT4) in hES-MSCs and hMSCs.
In contrast, WNT5A and WNT5B were detected at a higher
level in hESCs and up-regulated in hES-MSCs and hMSCs.
FZD genes and coreceptor LRP6 were detected at a
relatively high level in the three cell populations.
Wnt pathway inhibitors DKK1, and especially SFRP4,
were up-regulated in hMSCs (Figure 3(h)). SFRP4 was up-
regulated 150 times in hMSCs (NCt = 25.4) as compared to
hESCs(NCt =32.6)andhES-MSCs(NCt =31.5).SFRP4acts
by binding Wnt molecules in the extracellular space, thus
inducing Wnt pathway inhibition and it has been described
as an angiogenesis inhibitor [53].
Finally, WISP1 and WISP2 are downstream genes of the
WNT signaling pathway both involved in osteogenesis. As
compared to hESCs, WISP1 (NCt = 32) and WISP2 (NCt >
35) were both strongly up-regulated in hES-MSCs and
hMSCs (Tables 1). As shown in Figure 3(i), WISP2 was not
detected in hESCs and was up-regulated 13 times in hES-
MSCs (NCt = 30.8) and 950 times in hMSCs (NCt = 24.8).
This gene is up-regulated during bone formation, especially
under Wnt3a stimulation [54].
3.4. CD34. CD34 (Figure 3(j)) is the most common antigen
used as a marker to select human hematopoietic stem cells
[55]. We observed that the CD34 gene was signiﬁcantly
expressed by hESCs, down-regulated 8 times but still signiﬁ-
cantly expressed by hES-MSCs and not detected in hMSCs.
As suggested for some receptors with a low expression in
hESC-MSCs and no expression in hMSCs, this antigen could
therefore be used to enrich more primitive hMSCs. Such
suggestion is in agreement with studies using anti-CD34
antibodies to select hMSC progenitors from adult bone
marrow [56, 57] or, more recently, from hES-MSCs [9].
4. Conclusions
Sensitive and quantitative comparisons of developmental
gene expression in hESCs, hES-MSCs, and hMSCs provide a
wealth of information to better characterize the phenotypes
and developmental controls of the most primitive hMSCs.
Our transcriptomic study validates other observations
suggesting that hES-MSCs constitute a more primitive
population than hMSCs. In particular we observe a greater
expression of mesodermal genes including sarcomeric mus-
cle genes in hES-MSCs. This validates previous observations
that primitive hMSCs, such as MAPC, could diﬀerentiate
towards sarcomeric muscle cells [18].
Our data suggest diﬀerent ways by which hMSCs could
interact with stem cells of various niches. IL-8, PDGFA
and FLT3 ligand, but not their receptors, are well expressed
by hMSCs, suggesting a paracrine action in niches such as
the hematopoietic one. FLT3 Ligand gene expression is not
surprising in the hematopoietic niche, as it plays a major
role in the self-renewal of primitive hematopoietic stem cells.
Latent TGF-β is present throughout the ECM of stem cell
niches. This molecule can interfere with the leucine-rich
repeat-containing protein 32 receptor (LRRC32) expressed
by hMSCs and can thus release active TGF-β peptides
locally.
Gene expression comparisons in the three populations
allow the identiﬁcation of 5 membrane receptors that are
potential markers enriched in the most primitive hMSCs.
In agreement with diﬀerent studies on receptorlow stem cell
selection [21–29], our results suggest that primitive hMSCs
might be IL1R1low,B M P R - 1 B low,P T H R 1 low,F L T 4 low,a n d
LRRC32low. We also indicated that these cells could be
CD34+, as recently validated [9].
hMSCs are a mixture of rare primitive stem cells with a
majority of late progenitors. For this reason, transcriptomic
studies of primitive hMSCs would be inaccurate if total
hMSCs were used. Moreover, it would be extremely diﬃcult
to validate all the gene expression data of a transcriptomic
study using the single cell experiments necessary to charac-
terize the most primitive adult stem cells. In this study, our
comparison of sensitive and quantitative gene expression in
the three cell populations validates previous observations,
some of which have been diﬃcult to reproduce, on primitive
hMSCs. Furthermore this methodology could pinpoint
genes of interest encoding proteins not yet characterized and
be fruitfully applied to other type of adult stem cells.
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